Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ORCHARD)
Complete Title: A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced
Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line
Osimertinib Therapy
Trial Phase: II
Investigator: Christina Baik
Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.
Keywords:
- Lung Cancer
- Lung Carcinoma, Non-Small-Cell (NSCLC)
- Neoplasms, Bronchial
- Neoplasms, Thoracic
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
II
Christina Baik
RG1005292
NCT03944772
A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced
Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line
Osimertinib Therapy
Lung Cancer
Lung Carcinoma, Non-Small-Cell (NSCLC)
Neoplasms, Bronchial
Neoplasms, Thoracic